A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity
- PMID: 2189784
- DOI: 10.1016/0378-1119(90)90032-m
A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity
Abstract
A microtransfection method, using either the DEAE-dextran or the Ca.phosphate procedure has been developed. A plasmid expressing the luciferase-encoding gene under the control of the human immunodeficiency virus (HIV) LTR promoter was constructed. Transfections were performed in 96-well plates, allowing statistical evaluation of the results. This microtransfection method requires the use of 100- to 1000-fold less plasmid and cells than in a conventional chloramphenicol acetyl transferase (CAT) assay. A Luciferase index which takes into account cell viability after transfection has been defined using a semi-automated absorbance assay. A 20-h incubation period post-transfection is sufficient for optimal results. Basal long terminal repeat activity and autologous Tat transactivation were studied in various lymphoid, monocytic and adherent human cell lines. Infection of microtransfected cells by HIV activated luc expression. This assay can thus also be used for rapid detection and quantitation of HIV. Antiviral activities of drugs can be assessed in a two-day test.
Similar articles
-
HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.AIDS. 1997 Feb;11(2):139-46. doi: 10.1097/00002030-199702000-00002. AIDS. 1997. PMID: 9030359
-
Transactivation of heterologous promoters by HIV-1 tat.Nucleic Acids Res. 1991 Dec;19(25):7225-9. doi: 10.1093/nar/19.25.7225. Nucleic Acids Res. 1991. PMID: 1662814 Free PMC article.
-
Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.Gene Ther. 1996 Aug;3(8):725-30. Gene Ther. 1996. PMID: 8854098
-
Cellular factors regulate transactivation of human immunodeficiency virus type 1.J Virol. 1991 Mar;65(3):1392-9. doi: 10.1128/JVI.65.3.1392-1399.1991. J Virol. 1991. PMID: 1995949 Free PMC article.
-
A sensitive promoter assay based on the transcriptional activator Tat of the HIV-1 virus.Gene. 1994 Jul 8;144(2):243-7. doi: 10.1016/0378-1119(94)90384-0. Gene. 1994. PMID: 8039709
Cited by
-
The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation.EMBO J. 1992 Jan;11(1):195-203. doi: 10.1002/j.1460-2075.1992.tb05042.x. EMBO J. 1992. PMID: 1740105 Free PMC article.
-
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4653-8. doi: 10.1073/pnas.94.9.4653. Proc Natl Acad Sci U S A. 1997. PMID: 9114046 Free PMC article.
-
Inhibition of transcription factors belonging to the rel/NF-kappa B family by a transdominant negative mutant.EMBO J. 1991 Jul;10(7):1827-32. doi: 10.1002/j.1460-2075.1991.tb07708.x. EMBO J. 1991. PMID: 1675604 Free PMC article.
-
Statins inhibit HIV-1 infection by down-regulating Rho activity.J Exp Med. 2004 Aug 16;200(4):541-7. doi: 10.1084/jem.20040061. J Exp Med. 2004. PMID: 15314078 Free PMC article.
-
Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes.J Virol. 2005 May;79(9):5386-99. doi: 10.1128/JVI.79.9.5386-5399.2005. J Virol. 2005. PMID: 15827153 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
